62nd ASH Annual Meeting and Exposition: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III

Oral and Poster Abstracts
Poster

antibodies, apoptosis, Biological, multiple myeloma, therapy sequence, bone marrow, Diseases, Non-Biological, Combinations, Therapies, Adverse Events, cellular interactions, Biological Processes, Technology and Procedures, Cell Lineage, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, NK cells, pharmacology, immune mechanism, microenvironment, pathogenesis, pathways

3188

A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma

Tengteng Yu, MD¹^*, Bharat Chaganty²^*, Liang Lin, PhD³^*, Lijie Xing, MD³^*, Boopathy Ramakrishnan⁴^*, Kenneth Wen³^*, Phillip A Hsieh⁵^*, Andrew Wollacott⁴^*, Karthik Viswanathan⁴^*, Hedy Adari²^*, Shih-Feng Cho, MD, PhD⁶^*, Yuyin Li, PhD⁷^*, Wenjuan Yang⁷^*, Hailin Chen⁷^*, Yan Xu, MD⁸^*, Gang An⁹^*, Lugui Qiu, MD¹⁰, Nikhil C. Munshi, MD¹¹, Gregory Babcock⁴^*, Zach Shriver⁴^*, James Myette, PhD¹²^*, Kenneth Anderson, MD¹³ and Yu-Tzu Tai, PhD¹¹

¹Dana-Farber Cancer Institute, Brookline, MA
²Visterra Inc., Walthem, MA
³Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
⁴Visterra Inc, Waltham
⁵Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute,, Boston, MA
⁶Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
⁷Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston
⁸The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁹Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
¹⁰lymphoma and myeloma center, National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
¹¹Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹²Visterra Inc., Waltham, MA
¹³Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3189

TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment

Jiye Liu, PhD¹^*, Teru Hideshima, MD, PhD², Lijie Xing, MD¹^*, Su Wang, PhD³^*, Daisuke Ogiya, MD, PhD⁴^*, Mehmet K. Samur, PhD¹, Nikhil C. Munshi, MD^5,6, Paul G. Richardson, MD⁷, Kenneth Wen⁸^*, Yu-Tzu Tai, PhD⁶, Yong Cang, PhD⁹^* and Kenneth Anderson, MD¹⁰

¹The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Department of Biomedical Informatics, Harvard Medical School, Boston, MA
⁴The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁶Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁸Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
⁹School of Life Science and Technology, ShanghaiTech University, Shanghai, China
¹⁰Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3190

Adipocyte Fatty Acid Binding Protein Promotes Multiple Myeloma through Regulating Bone Marrow Microenvironment

Lingling Shu, MD, PhD^1,2^*, Jinyuan Li¹^*, Weida Wang, MD, PhD¹^*, Xiaoping Wu, PhD²^*, Hanying Huang¹^*, Fang Hu¹^* and Yang Liang, MD^3,4

¹State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
²State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China
³Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
⁴Yale University School of Medicine Yale Cancer Center, New Haven, CT

3191

A Novel Therapeutic Strategy for Preferential Elimination of Multiple Myeloma Cells By Targeting Protein Disulfide Isomerase

Metis Hasipek, PhD¹^*, Dale Grabowski, BS¹^*, Yihong Guan, PhD¹^*, Anand D. Tiwari, PhD¹^*, Xiaorong Gu, PhD¹^*, Jason Valent, MD², Jaroslaw Maciejewski, PhD¹^*, Frederic Joel Reu³, James G Phillips, PhD¹^* and Babal K. Jha, PhD¹^*

¹Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
²Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
³H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC, Tampa, FL

3192

Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition

Yan Xu, MD^1,2^*, Yao Yao³^*, Woojun Daniel Park⁴, Sanika Derebail, MS⁵^*, Chandraditya Chakraborty, PhD⁶^*, Shidai Mu²^*, Rafael Alonso Fernández^2,7^*, Srikanth Talluri, PhD^8,9^*, Zuzana Chyra, PhD^10,11,12^*, Kenneth Wen¹³^*, Qingsheng Yan³^*, Osasenaga Idahor³^*, Selene Cipri³^*, Rao Prabhala^9,14, Kenneth Anderson, MD¹⁵, Mehmet K. Samur, PhD¹⁶^*, Mariateresa Fulciniti, PhD¹⁷ and Nikhil C. Munshi, MD^9,18

¹Institute of Hematology & Blood Diseases Hospital, Department of Lymphoma & Myeloma, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
³Dana Farber Cancer Institute, Boston, MA
⁴Baylor College of Medicine, Houston, TX
⁵Dana-Farber Cancer Institute, Boston, MA
⁶Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁷Translational Hematology Group, Hospital 12 de Octubre-CNIO, Madrid, Spain
⁸The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, West Roxbury, MA
⁹VA Boston Healthcare System, Boston, MA
¹⁰University Hospital Ostrava, Department of Haemato-Oncology, Ostrava, Czech Republic
¹¹Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
¹²Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston
¹³Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Boston, MA
¹⁴DFCI/VABHS/Harvard Med. School, West Roxbury, MA
¹⁵Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁶The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹⁷Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

3193

Carfilzomib-Induced Hypertension Is Mediated By Ion Channel Dysregulation in the Kidneys; The Potent Role of AMP-Activated Kinase α

Panagiotis Efentakis, PhD¹^*, Sofia Lamprou¹^*, Polyzois Dimas¹^*, Constantinos Dimitriou, PhD²^*, Manousos Makridakis, PhD²^*, Maria Tsoumani, PhD¹^*, Asimina Papanikolaou, MD³^*, Efstathios Kastritis, MD⁴^*, Antonia Vlachou, PhD²^*, Meletios A Dimopoulos⁵, Ioanna Andreadou, PhD¹^* and Evangelos Terpos, MD, PhD⁵

¹Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece
²Biomedical Research Foundation of the Academy of Athens, Athens, Greece
³Department of Hemopathology, "Evangelismos" General Hospital, Athens, Greece
⁴Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, ATHENS, Greece
⁵Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

3194

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Suzette Girgis, PhD, BPharm, MS¹, Shun Xin Wang Lin, PhD²^*, Kodandaram Pillarisetti, MSc³^*, Arnob Banerjee, MD²^*, Jenna D. Goldberg, MD⁴^*, Shoba Shetty, PhD⁵^*, Tara Stephenson, PhD²^*, Brandi W. Hilder, PhD²^*, Brett Hanna⁶^*, Jennifer Smit⁴^*, Homer Adams III, PhD⁷^*, Yu-Nien (Tom) Sun, PhD⁸, Jeffrey R. Infante, MD²^*, Yusri A Elsayed, MD, PhD²^* and Amarnath Sharma, PhD⁵^*

¹Janssen R&D, Princeton, NJ
²Janssen R&D, Spring House, PA
³Janssen Pharamaceuticals, Spring House, PA
⁴Janssen R&D, Raritan, NJ
⁵Janssen Research & Development, LLC, Spring House, PA
⁶Janssen Research & Development, Malvern, PA
⁷Genmab, Princeton
⁸Janssen R&D LLC, Spring House, PA

3195

A Novel Aryl-Guanidinium Based Compound Targets the STAT3 Signalling Pathway, Downregulates MCL-1 Expression and Induces Anti-Myeloma Activity

Rebecca Amet, PhD^1,2^*, Viola Previtali, PhD³^*, Helene Mihigo, BSc³^*, Emily Sheridan, BA(Mod)¹^*, Sarah Brophy, PhD²^*, Patrick J Hayden, MD⁴, Paul V Browne, MB, FRCPath⁴, Isabel Rozas, PhD³^*, Daniela Zisterer, PhD¹^* and Tony M McElligott, PhD²^*

¹School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland
²Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland
³School of Chemistry, Trinity College Dublin, Dublin, Ireland
⁴Department of Haematology, St. James's Hospital, Dublin, Ireland

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH